Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 25-29

  Slavin, Shimon ^a   Nagler, Arnon ^a   Shapira, Michael ^a   Panigrahi, Soumya ^a   Samuel, Simcha ^a   Or, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

BMT; Cell therapy; DLI; Fludarabine; Hematologic malignancies; Leukemia; Mini transplant; NST

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYELOABLATIVE AGENT; THYMOCYTE ANTIBODY;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; CANCER IMMUNOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DONOR; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC SYSTEM; HOST CELL; HUMAN; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; RECIPIENT; STEM CELL TRANSPLANTATION; TOXICITY; TUMOR CELL;

ACUTE DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034971850     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00121-4     Document Type: Conference Paper

References (17)

1. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
2. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT)
3. New developments in bone marrow transplantation
4. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT)
5. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
6. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
7. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
8. Spontaneous murine B-cell leukemia
9. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
10. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy
11. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2
12. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma
13. Allogeneic cell therapy for a murine mammary carcinoma
14. Immunotherapy of leukemia in conjunction with non-myeloablative conditioning: engraftment of blood stem cells and eradication of host leukemia with nonmyeloablative conditioning based on Fludarabine and anti-thymocyte globulin (ATG)
15. Non-myeloablative conditioning in preparation for allogeneic stem cell transplantation: the future treatment of choice of hematologic malignancies and genetic diseases
16. Successful replacement of conventional bone marrow transplantation with high-dose chemoradiotherapy with well tolerated nonmyeloablative conditioning in preparation for allogeneic blood stem cell transplantation for the treatment of malignant and non-malignant diseases
17. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases